By FRANKFURT (Reuters) – Sanofi (NASDAQ:SNY) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
The company said earlier this month that the late-stage trial with the drug candidate tolebrutinib was successful.
This post appeared first on investing.com